Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patientsFootnote^*

* The data have already been partially presented at the 14th EACS in Brussels, Belgium on 16–19 October 2013.

References

• HIV-CAUSAL Collaboration, Ray M, Logan R, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24:123–137.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655.10.1016/S0140-6736(08)61081-8
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323–332.10.1097/QAI.0b013e3181c990bf
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445–456.10.7326/0003-4819-154-7-201104050-00316
   PubMed Web of Science ®Google Scholar
• Clumeck N, Molina J, Henry K, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1 infected patients: week 144 results. J Acquir Immune Defic Syndr. 2014;65:e121–e124.10.1097/QAI.0000000000000089
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711–718.10.1097/01.aids.0000216371.76689.63
   PubMed Web of Science ®Google Scholar
• De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients. The data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–1229.10.2337/dc07-2013
   PubMed Web of Science ®Google Scholar
• Elzi L, Marzolini C, Hanjakob H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170:57–65.10.1001/archinternmed.2009.432
   PubMed Web of Science ®Google Scholar
• Teófilo E, Knechten H, Antela A, et al. Long-term efficacy and safety of atazanavir/ritonavir treatment in a cohort of treatment-naïve HIV patients: an interim analysis of the REMAIN study. Abstract for the eleventh international congress on drug therapy in HIV infection. J Int AIDS Soc. 2012;15:18248.
   Web of Science ®Google Scholar
• Svedhem-Johansson V, Pugliese P, Brockmeyer NH, et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r) – containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11:333–341.10.2174/1570162X113119990037
   PubMed Web of Science ®Google Scholar
• Tremblay C, Trottier B, Rachlis A, et al. Treatment durability, effectiveness, and safety wsith atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients. HIV Clin Trials. 2011;12:151–160.10.1310/hct1203-151
   PubMed Web of Science ®Google Scholar
• Elion R, deJesus E, Sension M, et al. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study. HIV Clin Trials. 2008;9:152–163.10.1310/hct0903-152
   PubMed Web of Science ®Google Scholar
• Jansen K, Sönnerborg A, Brockmeyer N, et al. Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses. 2013;29:564–573.10.1089/aid.2012.0092
   PubMed Web of Science ®Google Scholar
• Smith KY, Tierney C, Mollan K, et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis. 2014;58:555–563.10.1093/cid/cit747
   PubMed Web of Science ®Google Scholar
• Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS. 2001;15:71–75.10.1097/00002030-200101050-00011
   PubMed Web of Science ®Google Scholar
• Vo TT, Ledergerber B, Keiser O, et al. Durability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV cohort study. J Infect Dis. 2008;197:1685–1694.10.1086/590464
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Behrens G, Genschel J, et al. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antivir Ther. 1999;4:163–170.
   PubMed Web of Science ®Google Scholar
• Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641–649.10.1097/00002030-200403050-00008
   PubMed Web of Science ®Google Scholar
• Souza SJ, Luzia LA, Santos SS, et al. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras. 2013;59:186–198.10.1016/j.ramb.2012.11.003
   PubMed Web of Science ®Google Scholar
• Pavie J, Porcher R, Torti C, et al. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1 infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother. 2011;66:2372–2378.10.1093/jac/dkr316
   PubMed Web of Science ®Google Scholar
• Zamora L, Gatell JM. Efficacy of atazanavir in simplification regimens. Enferm Infecc Microbiol Clin. 2008;26:14–21.10.1016/S0213-005X(08)76615-1
   PubMedGoogle Scholar